Genome-Based Therapeutics Targeted Drug Discovery and Development: Workshop Summary (2012) / Chapter Skim
Currently Skimming:
6 Forging Collaborative Strategies for the Development of Personalized Medicine
6 Forging Collaborative Strategies for the Development of Personalized Medicine
Pages 47-54
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 47... ...
· A particular focus of collaboration needs to be the establish ment of biorepositories, databases, patient repositories, and other information resources for drug development. · Universal participation in biomedical research is a goal that would require overcoming major obstacles, but it would gener ate an enormous amount of safety and efficacy data that would benefit everyone.
|
From page 48... ...
THE NEED FOR COLLABORATION Translating genomic discoveries into patient benefits is a "team sport," Dunsire said. No one organization has all the capabilities and resources needed to realize the promise of personalized medicine.
|
From page 49... ...
In that regard the parties to a collaboration need to recognize the potential threats to a collaborative enterprise. For example, efforts to protect intellectual property, either by industry or academic partners, can stymie partnerships and thereby limit scientific advances.
|
From page 50... ...
Many policies besides regulatory policies affect this ecosystem, including intellectual property protections, access to capital, reimbursement policies, and direct government investments. All of these policies matter, said Hamburg.
|
From page 51... ...
Examples like the collaboration between Millennium Pharmaceuticals and the Multiple Myeloma Research Foundation on the latter's Personalized Medicine Initiative discussed in Chapter 5 show what is possible, Dunsire said. Patients with the same genetic condition can be targeted, and patients with other mutations can be encouraged to participate in different trials.
|
From page 52... ...
Both phenotypic and genomic data, Dzau said, need to be gathered from multiple patient populations, including those suffering from rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, cardio vascular disease, and other diseases, not just cancer. The intention must be to apply information so that everyone is placed into a subpopulation.
|
From page 53... ...
Instead, payers, patients, and drug developers collect much of that value. Only when diagnostic companies have strong intellectual property protection have they been able to force other partners to pay what a diagnostic is worth.
|
From page 54... ...
Dzau agreed, adding that the social, cultural, and environmental influences on health point to the need to involve social scientists in collaborations. For instance, one way of involving social scientists would be to have anthropologists help develop culturally specific ways of encouraging participation and gathering information in research.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.